Welcome to our dedicated page for Annexon SEC filings (Ticker: ANNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Annexon SEC filings document a clinical-stage biopharmaceutical company developing C1q-targeted immunotherapies for neuroinflammatory and classical complement-mediated diseases. Its Form 8-K reports furnish operating results, portfolio progress, investor presentations, and strategic priority updates tied to programs such as vonaprument, tanruprubart, and ANX1502.
The company’s filings also cover proxy governance, annual meeting proposals, director elections, auditor ratification, executive compensation votes, board changes, and Nasdaq-listed common stock. Capital-structure disclosures include amendments to common stock purchase warrants and related rights of security holders.
Annexon, Inc. (NASDAQ: ANNX) filed a Form 144 disclosing a proposed insider sale of up to 853 common shares, valued at approximately $2,226.42. The shares, representing roughly 0.0008% of the 109.7 million shares outstanding, were acquired through restricted-stock vesting on 07 Jul 2025 and are slated for sale on or about 14 Jul 2025 via Fidelity Brokerage Services LLC on the NASDAQ exchange.
No other sales by the filer in the past three months were reported, and the filing contains the standard affirmation that the seller possesses no undisclosed material adverse information. Filer name and relationship to the issuer were not provided, suggesting an administrative notice rather than a significant ownership change.
Given the minimal share count and dollar value, this transaction is considered routine and unlikely to affect Annexon’s capital structure, liquidity, or share price. Investors typically view such small-scale Form 144 filings as non-material disclosures.
Annexon, Inc. (ANNX) has filed a Form 144 indicating the planned sale of 1,117 common shares through Fidelity Brokerage Services on 14 July 2025. The shares, valued at an aggregate $2,880.97, were acquired via restricted-stock vesting on 11 July 2025 as compensation. Outstanding shares total 109,714,404; therefore, the proposed sale represents roughly 0.001% of shares outstanding, a de-minimis amount that will not affect float or control. No other sales have occurred in the past three months, and the filer affirms no undisclosed material adverse information.